Bausch Health Cos (NYSE:BHC) Posts Earnings Results

Bausch Health Cos (NYSE:BHC) issued its quarterly earnings data on Wednesday. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03), Zacks reports. Bausch Health Cos had a positive return on equity of 503.18% and a negative net margin of 11.47%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion.

Here are the key takeaways from Bausch Health Cos’ conference call:

• Bausch Health (ex-Bausch + Lomb) reported a strong Q1 with 12 consecutive quarters of year-over-year revenue and adjusted EBITDA growth, revenue up ~14% (reported) and adjusted EBITDA up 17%, and management reaffirmed full‑year guidance.
• Growth was led by Xifaxan/Salix, but management reiterated risk around exclusivity—expecting a generic entrant by 1/1/2028 and a gross‑to‑net accrual adjustment effective 1/1/2027—creating downside risk to future cash flow and valuation.
• Solta delivered exceptional results driven by China after the December 2025 Shibo acquisition (reported Solta revenue +51%, China +193%), with integration cited as a durable competitive advantage for capital sales and consumables.
• Cash generation and deleveraging improved in Q1—net debt (ex-Bausch + Lomb) fell by ~$150 million, adjusted operating cash flow was strong, and U.S. opt‑out litigation payments concluded, supporting capital‑structure priorities.
• R&D and BD focus includes a U.S.-only, earlier‑randomized, highly powered larsucosterol Phase III program and continued screening of late‑stage/commercial assets; these could be value‑creating but remain execution‑ and trial‑outcome dependent.

Bausch Health Cos Trading Down 1.5%

Shares of BHC stock traded down $0.09 during trading hours on Friday, reaching $5.64. 2,241,845 shares of the stock were exchanged, compared to its average volume of 2,028,119. Bausch Health Cos has a 12-month low of $4.41 and a 12-month high of $8.69. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The company’s 50-day moving average price is $5.50 and its 200-day moving average price is $6.19. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -1.74 and a beta of 0.40.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of recent research reports. Truist Financial lifted their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Royal Bank Of Canada dropped their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research note on Monday. Finally, Barclays dropped their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 25th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $8.00.

Hedge Funds Weigh In On Bausch Health Cos

A number of large investors have recently made changes to their positions in BHC. Amundi bought a new stake in Bausch Health Cos during the 4th quarter valued at about $103,000. Orion Porfolio Solutions LLC bought a new stake in Bausch Health Cos during the 4th quarter valued at about $100,000. Commonwealth Equity Services LLC lifted its holdings in Bausch Health Cos by 14.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after buying an additional 1,812 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in Bausch Health Cos during the 3rd quarter valued at about $100,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Bausch Health Cos during the 3rd quarter valued at about $95,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.